



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-BAFF & IL-17A Reference Antibody (Tibulizumab)	Lot.No.:	P103472
Target:	TNFSF13B / BAFF / CD257, IL-17 / IL-17A / CTLA-8	Catalog:	CHBA001
Target Accession:	Q9Y275 & Q16552	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-scFv
Reactivity:	Human	Molecular Weight (kDa) :	201.44 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

MASS




The detected molecular weight of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 201.34 kDa.

Purity: SDS-PAGE




Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 92.06%, determined by SEC-HPLC.


Bioactivity: ELISA



Tibulizumab bound to BAFF protein, and then rebounded to secondary antibodies (Anti-human- κ - λ -HRP), and read OD450. As shown in fig, Tibulizumab bound hu-BAFF-Fc, and the EC50 was 0.081 nM.


The products are for research use only. Not for use in diagnostic procedures.

ELISA



Tibulizumab bound to IL-17a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Tibulizumab bound to in hu-IL-17a-His, and the EC50 was 0.128 nM.

Functional assay



Co-incubation of NHDF cells with TNF- α and IL-17A protein, then with the addition of Tibulizumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Tibulizumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 3.81 nM.

The products are for research use only. Not for use in diagnostic procedures.